Adjuvant Immunomodulatory (IM) Therapy

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIANCT04360265RAREPhase 3Enrolling by invitation2027-08Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.